Other papers submitted by: Professor Paola Rogliani

Back to User profile » Professor Paola Rogliani

Papers published by Professor Paola Rogliani:

Original Research

Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study

Cameli P, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Canonica GW, Caruso C, Centanni S, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Senna G, Vultaggio A, Benci M, Boarino S, Menzella F

Journal of Asthma and Allergy 2024, 17:273-290

Published Date: 27 March 2024

Original Research

Exacerbation Burden in COPD and Occurrence of Mortality in a Cohort of Italian Patients: Results of the Gulp Study

Santus P, Di Marco F, Braido F, Contoli M, Corsico AG, Micheletto C, Pelaia G, Radovanovic D, Rogliani P, Saderi L, Scichilone N, Tanzi S, Vella M, Boarino S, Sotgiu G, Solidoro P

International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:607-618

Published Date: 1 March 2024

Review

Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement

Manzetti GM, Ora J, Sepiacci A, Cazzola M, Rogliani P, Calzetta L

International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2225-2243

Published Date: 10 October 2023

Commentary

Can Treatable Traits Be the Approach to Addressing the Complexity and Heterogeneity of COPD?

Cazzola M, Rogliani P, Blasi F

International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1959-1964

Published Date: 8 September 2023

Original Research

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

Senna G, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Cameli P, Canonica GW, Caruso C, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, Rizzoli S, Zullo A, Boarino S, Palmisano M, Rossi A, Vitiello G, Centanni S

Journal of Asthma and Allergy 2022, 15:1593-1604

Published Date: 10 November 2022

Corrigendum

The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset [Corrigendum]

Calverley PMA, Papi A, Page C, Rogliani P, Dal Negro RW, Cazzola M, Cicero AF, Wedzicha JA

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2451-2452

Published Date: 3 October 2022

Original Research

The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset

Calverley PMA, Papi A, Page C, Rogliani P, Dal Negro RW, Cazzola M, Cicero AF, Wedzicha JA

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1909-1920

Published Date: 22 August 2022

Review

Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile

Rogliani P, Cavalli F, Chetta A, Cazzola M, Calzetta L

Journal of Asthma and Allergy 2022, 15:565-577

Published Date: 6 May 2022

Expert Opinion

Beyond Dual Bronchodilation – Triple Therapy, When and Why

Cazzola M, Rogliani P, Laitano R, Calzetta L, Matera MG

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:165-180

Published Date: 14 January 2022

Commentary

Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies

Rogliani P, Calzetta L

Journal of Experimental Pharmacology 2022, 14:1-5

Published Date: 11 January 2022

Review

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease

Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG

Biologics: Targets and Therapy 2021, 15:363-374

Published Date: 27 August 2021

Review

New Avenues for Phosphodiesterase Inhibitors in Asthma

Matera MG, Ora J, Cavalli F, Rogliani P, Cazzola M

Journal of Experimental Pharmacology 2021, 13:291-302

Published Date: 15 March 2021

Review

The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review

Calzetta L, Coppola A, Ritondo BL, Matino M, Chetta A, Rogliani P

International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:257-279

Published Date: 12 February 2021

Review

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease

Ora J, Coppola A, Cazzola M, Calzetta L, Rogliani P

Journal of Experimental Pharmacology 2020, 12:559-574

Published Date: 8 December 2020

Review

Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy

Cazzola M, Rogliani P, Calzetta L, Matera MG

Pharmacogenomics and Personalized Medicine 2020, 13:261-271

Published Date: 4 August 2020

Review

Day and Night Control of COPD and Role of Pharmacotherapy: A Review

Braghiroli A, Braido F, Piraino A, Rogliani P, Santus P, Scichilone N

International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1269-1285

Published Date: 4 June 2020

Original Research

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM

Risk Management and Healthcare Policy 2020, 13:43-53

Published Date: 22 January 2020

Clinical Trial Report

Disease awareness in patients with COPD: measurement and extent

Baiardini I, Rogliani P, Santus P, Corsico AG, Contoli M, Scichilone N, Di Marco F, Lessi P, Scognamillo C, Molinengo G, Ferri F, Patella V, Fiorentino G, Carone M, Braido F

International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:1-11

Published Date: 17 December 2018

Corrigendum